scholarly journals Expression of Luteinizing Hormone-Releasing Hormone (LHRH) and Type-I LHRH Receptor in Transitional Cell Carcinoma Type of Human Bladder Cancer

Molecules ◽  
2021 ◽  
Vol 26 (5) ◽  
pp. 1253
Author(s):  
Zsuzsanna Szabó ◽  
Balázs Dezső ◽  
Klára Fodor ◽  
Krisztián Szegedi ◽  
Tibor Flaskó ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Luteinizing Hormone ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Transitional Cell ◽  
Type I ◽  
Human Bladder ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
Lhrh Receptor

Bladder cancer (BC) is the tenth most frequently detected cancer in both sexes. Type-I luteinizing hormone-releasing hormone (LHRH) receptor (LHRH-R-I) is expressed not only in the pituitary, but also in several types of cancer disease. There are few data about LHRH-R-I expression in human BC. This study aimed to investigate the expression of LHRH and LHRH-R-I in the transitional cell carcinoma (TCC) type of human BC. RNA was extracted from 24 human bladder tumor specimens and three BC cell lines. RT-PCR was performed to detect mRNA for LHRH and LHRH-R-I. The protein of LHRH-R-I was further studied by immunohistochemistry (IHC), ligand competition assay, and Western Blot. PCR products of LHRH were found in 19 of 24 (79%) specimens and mRNA of LHRH-R-I was detected in 20 of 24 specimens (83%). Positive immunostaining for LHRH-R-I with different expression intensity was found in all samples examined, showing negative correlation with TCC grade. Radioligand binding studies also showed the presence of specific LHRH-R-I and high affinity binding of LHRH analogs. The high incidence of LHRH-R in BC suggests that it could serve as a molecular target for therapy of human BC with cytotoxic LHRH analogs or modern powerful antagonistic analogs of LHRH.

scholarly journals Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma

Oncotarget ◽  
2013 ◽  
Vol 4 (10) ◽  
pp. 1721-1728 ◽  
Author(s):  
Andrea Treszl ◽  
Zita Steiber ◽  
Andrew V. Schally ◽  
Norman L Block ◽  
Balazs Dezso ◽  
...  
Keyword(s):  
Luteinizing Hormone ◽  
Uveal Melanoma ◽  
Receptor Type ◽  
Type I ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
Lhrh Receptor

405: Previous History of Bladder Cancer is an Independent Prognostic Factor for Upper Tract Transitional Cell Carcinoma

2007 ◽  
Vol 177 (4S) ◽  
pp. 135-135
Author(s):  
Eiji Kikuchi ◽  
Akira Miyajima ◽  
Ken Nakagawa ◽  
Mototsugu Oya ◽  
Takashi Ohigashi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Prognostic Factor ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Transitional Cell ◽  
Previous History ◽  
Independent Prognostic Factor ◽  
Upper Tract ◽  
History Of

scholarly journals Paraneoplastic production of heparin-like anticoagulant in a patient with metastatic transitional cell carcinoma

2013 ◽  
Vol 3 (5) ◽  
pp. 61 ◽  
Author(s):  
Kelly N. Fahl ◽  
Stephen A. Poon ◽  
Ketan K. Badani ◽  
Mitchell C. Benson
Keyword(s):  
Bladder Cancer ◽  
Breast Carcinoma ◽  
Liver Failure ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Hematological Malignancies ◽  
Transitional Cell ◽  
Carcinoma Breast ◽  
Severe Coagulopathy

It has been reported that patients with bladder cancer have widelyvarying paraneoplastic consequences, including metabolic, dermatologic,myopathic and neurologic disturbances. We report a case of a52-year-old man with advanced transitional cell carcinoma and livermetastases, who developed a severe coagulopathy following roboticradical cystoprostatectomy due to circulating heparin-like substancesprior to onset of liver failure. Heparin-like anticoagulant production isa rare paraneoplastic effect documented in concert with transitionalcell carcinoma, breast carcinoma and hematological malignancies.

Repeated Intravesical Instillations of an Adenoviral Vector in Patients With Locally Advanced Bladder Cancer: A Phase I Study of p53 Gene Therapy

2003 ◽  
Vol 21 (12) ◽  
pp. 2247-2253 ◽  
Author(s):  
Lance C. Pagliaro ◽  
Afsaneh Keyhani ◽  
Dallas Williams ◽  
Denise Woods ◽  
Baoshun Liu ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Bladder Cancer ◽  
Gene Transfer ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Locally Advanced ◽  
Transitional Cell ◽  
P53 Gene ◽  
Advanced Bladder Cancer ◽  
Intravesical Instillations

Purpose: We investigated the feasibility, safety, and biologic activity of adenovirus-mediated p53 gene transfer in patients with locally advanced bladder cancer. Patients and Methods: Patients with measurable, locally advanced transitional-cell carcinoma of the bladder who were not candidates for cystectomy were eligible. On a 28-day cycle, intravesical instillations of INGN 201 (Ad5CMV-p53) were administered on days 1 and 4 at three dose levels (1010 particles to 1012 particles) or on either 4 or 8 consecutive days at a single dose level (1012 particles). Results: Thirteen patients received a total of 22 courses without dose-limiting toxicity. Specific transgene expression was detected by reverse transcriptase polymerase chain reaction in bladder biopsy tissue from two of seven assessable patients. There were no changes in p53, p21waf1/cip1, or bax protein levels in bladder epithelium evident from immunohistochemical analysis of 11 assessable patients. Outpatient administration of multiple courses was feasible and well tolerated. A patient with advanced superficial bladder cancer showed evidence of tumor response. Conclusion: Intravesical instillation of Ad5CMV-p53 is safe, feasible, and biologically active when administered in multiple doses to patients with bladder cancer. Observations from this study indicate that this treatment has an antitumor effect in superficial transitional-cell carcinoma. Improvements in the efficiency of gene transfer and the levels of gene expression are required to develop more effective gene therapy for bladder cancer.

Sign in / Sign up

Export Citation Format

Share Document